Question-and-Answer Session
Operator
Thank you. (Operator instructions) Now we'll go first to Terence Flynn with Lazard Capital Markets.
Terence Flynn – Lazard Capital Markets
Hi, good morning. Thanks for taking the questions. First off, I’m just wondering if you are going to reiterate your guidance of interim data from the ATC trial in mid 2009 or if you think, given where we stand on a number sites and enrollment, that that might slip into later 2009.
Richard Chin
I’ll address that question and I'll ask John to further comment. At this point, we are still looking at enrollment data and we’re not in a position to make any changes to that timeline. John, do you want to –?
John Kollins
Yes. I forgot. I think that, as I've come on kind of stepped into the COO role, one of the things I’m doing is working with the team, looking closely at all the goals. To the extent there’s data that drives any adjustments, we need to get our hands around that data and make adjustments accordingly. But at this point, we don’t see a need to do that.
Terence Flynn – Lazard Capital Markets
Okay, great. And then just on the topical formulation, what do you guys think in terms of the number of months of additional preclinical work that might be required before you can actually get this thing into man? What are your kind of latest thoughts there? I know you said you’d update us at a later time, but can you just give a sense of perhaps how much additional pre-clinical work do you have left?
Richard Chin
That question of preclinical work done – we're making sure that we have the optimal strategy for adjusting to this very large market. So, at this point, we won’t be giving specific items, but what I think is that there's a lot of the excitement both among physicians as well as potential partners for ophthalmology program.
John Kollins
And just to amplify on that a little bit, Terence, I think it’s not really a question of how much more clinical or preclinical development we do. It’s really a question of what’s the best overall drug development strategy for that program that lets us get as much data pre-clinically in order to best inform us in the clinic and there’s a variety of options there and we’re getting expert input into how that strategy unfolds.
- To read the full transcript on Seeking Alpha, click here »
